Download PDF
Semin Respir Crit Care Med 2023; 44(02): 260-268
DOI: 10.1055/s-0042-1758731
Review Article

Advanced Cystic Fibrosis Lung Disease and Lung Transplantation in the Era of Cystic Fibrosis Transmembrane Conductance Regulator Modulators

Mark O'Carroll
1   Respiratory Services, Auckland City Hospital, Te Toka Tumai, Te Whatu Ora – Health New Zealand, Auckland, New Zealand
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have changed the clinical landscape of cystic fibrosis (CF) by improving clinically significant outcome measures and quality of life of people with CF (pwCF). There are now long-term data showing improved 5-year survival with the use of ivacaftor, and the field continues to evolve at a rapid pace with the continued development of highly effective CFTR modulators. While the randomized controlled trials of CFTR modulators excluded patients with severe lung disease (forced expiratory volume in 1 second <40% predicted), observational data based on case reports and registry data show similar benefits in those with advanced lung disease. This has altered clinical practice particularly as it pertains to the role of lung transplantation in CF. This article describes the impact of highly effective modulator therapy (HEMT) on the natural history of CF and the influence on the timing of referral and consideration of listing for lung transplantation. CF clinicians play a pivotal role to ensure that the impetus of the CF foundation consensus guidelines to facilitate timely referral for lung transplantation is not lost among the excitement of anticipated sustained benefit from HEMT. While the widespread availability of elexacaftor/tezacaftor/ivacaftor over the past 2 years has been associated with a sharp drop in the number of people referred for consideration for lung transplantation and the number of people wait-listed for lung transplantation, it is difficult to accurately determine the true impact due to the confounding effect of the coronavirus disease 2019 pandemic. It is expected that lung transplantation will remain an important treatment for a smaller number of pwCF. Lung transplantation offers survival benefits in CF, and there remains an imperative to ensure timely consideration of lung transplantation in patients with advanced disease to further reduce the number of pwCF dying without consideration of lung transplant.

Keywords

cystic fibrosis - CFTR modulators - highly effective modulator therapy


Publication History

Article published online:
09 March 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 De Boeck K, Amaral MD. Progress in therapies for cystic fibrosis. Lancet Respir Med 2016; 4 (08) 662-674
    CrossrefPubMedGoogle Scholar
  • 2 Duckers J, Lesher B, Thorat T. et al. Real-world outcomes of ivacaftor treatment in people with cystic fibrosis: a systematic review. J Clin Med 2021; 10 (07) 1527-1557
    CrossrefPubMedGoogle Scholar
  • 3 Thabut G, Christie JD, Mal H. et al. Survival benefit of lung transplant for cystic fibrosis since lung allocation score implementation. Am J Respir Crit Care Med 2013; 187 (12) 1335-1340
    CrossrefPubMedGoogle Scholar
  • 4 Middleton PG, Mall MA, Dřevínek P. et al; VX17-445-102 Study Group. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med 2019; 381 (19) 1809-1819
    CrossrefPubMedGoogle Scholar
  • 5 Leard LE, Holm AM, Valapour M. et al. Consensus document for the selection of lung transplant candidates: an update from the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2021; 40 (11) 1349-1379
    CrossrefPubMedGoogle Scholar
  • 6 Ramos KJ, Smith PJ, McKone EF. et al; CF Lung Transplant Referral Guidelines Committee. Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines. J Cyst Fibros 2019; 18 (03) 321-333
    CrossrefPubMedGoogle Scholar
  • 7 Ramsey BW, Davies J, McElvaney NG. et al; VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365 (18) 1663-1672
    CrossrefPubMedGoogle Scholar
  • 8 Davies JC, Wainwright CE, Canny GJ. et al; VX08-770-103 (ENVISION) Study Group. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med 2013; 187 (11) 1219-1225
    CrossrefPubMedGoogle Scholar
  • 9 McKone EF, Borowitz D, Drevinek P. et al; VX08-770-105 (PERSIST) Study Group. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST). Lancet Respir Med 2014; 2 (11) 902-910
    CrossrefPubMedGoogle Scholar
  • 10 Barry PJ, Plant BJ, Nair A. et al. Effects of ivacaftor in patients with cystic fibrosis who carry the G551D mutation and have severe lung disease. Chest 2014; 146 (01) 152-158
    CrossrefPubMedGoogle Scholar
  • 11 Taylor-Cousar J, Niknian M, Gilmartin G, Pilewski JM. VX11-770-901 investigators. Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: safety and efficacy in an expanded access program in the United States. J Cyst Fibros 2016; 15 (01) 116-122
    CrossrefPubMedGoogle Scholar
  • 12 Sawicki GS, McKone EF, Pasta DJ. et al. Sustained benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data. Am J Respir Crit Care Med 2015; 192 (07) 836-842
    CrossrefPubMedGoogle Scholar
  • 13 Volkova N, Moy K, Evans J. et al. Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries. J Cyst Fibros 2020; 19 (01) 68-79
    CrossrefPubMedGoogle Scholar
  • 14 Burgel PR, Durieu I, Chiron R. et al; French Cystic Fibrosis Reference Network Study Group. Rapid improvement after starting Elexacaftor-Tezacaftor-Ivacaftor in patients with cystic fibrosis and advanced pulmonary disease. Am J Respir Crit Care Med 2021; 204 (01) 64-73
    CrossrefPubMedGoogle Scholar
  • 15 Bermingham B, Rueschhoff A, Ratti G. et al. Short-term effect of elexacaftor-tezacaftor-ivacaftor on lung function and transplant planning in cystic fibrosis patients with advanced lung disease. J Cyst Fibros 2021; 20 (05) 768-771
    CrossrefPubMedGoogle Scholar
  • 16 O'Shea KM, O'Carroll OM, Carroll C. et al. Efficacy of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease. Eur Respir J 2021; 57 (02) 2003079
    CrossrefPubMedGoogle Scholar
  • 17 Bear CE. A therapy for most with cystic fibrosis. Cell 2020; 180 (02) 211
    CrossrefPubMedGoogle Scholar
  • 18 Chambers DC, Cherikh WS, Harhay MO. et al; International Society for Heart and Lung Transplantation. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-sixth adult lung and heart-lung transplantation Report-2019; Focus theme: donor and recipient size match. J Heart Lung Transplant 2019; 38 (10) 1042-1055
    CrossrefPubMedGoogle Scholar
  • 19 Valapour M, Lehr CJ, Skeans MA. et al. OPTN/SRTR 2020 Annual data report: Lung. Am J Transplant 2022; 22 (suppl (Suppl. 02) 438-518
    CrossrefPubMedGoogle Scholar
  • 20 Global observation on donation and transplantation (global 2000–2022). Accessed September 27, 2022 at: http://www.transplant-observatory.org
    PubMedGoogle Scholar
  • 21 A phase 3 study of VX-121 combination therapy in participants with cystic fibrosis 9CF) heterozygous for F508del and a minimal function mutation (F/MF). Accessed September 27, 2022 at: https://clinicaltrials.gov/ct2/show/NCT05033080
    PubMedGoogle Scholar
  • 22 Griese M, Costa S, Linnemann RW. et al. Safety and efficacy of elexacaftor/tezacaftor/ivacaftor for 24 weeks or longer in people with cystic fibrosis and one or more F508del alleles: Interim results of an open-label phase 3 clinical trial. Am J Respir Crit Care Med 2021; 203 (03) 381-385
    CrossrefPubMedGoogle Scholar
  • 23 Kerem E, Reisman J, Corey M, Canny GJ, Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992; 326 (18) 1187-1191
    CrossrefPubMedGoogle Scholar
  • 24 Nkam L, Lambert J, Latouche A, Bellis G, Burgel PR, Hocine MN. A 3-year prognostic score for adults with cystic fibrosis. J Cyst Fibros 2017; 16 (06) 702-708
    CrossrefPubMedGoogle Scholar
  • 25 George PM, Banya W, Pareek N. et al. Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007. BMJ 2011; 342: d1008
    CrossrefPubMedGoogle Scholar
  • 26 Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. BMC Health Serv Res 2017; 17 (01) 88
    CrossrefPubMedGoogle Scholar
  • 27 Ramos KJ, Guimbellot JS, Valapour M. et al; CFLTC Study Group. Use of elexacaftor/tezacaftor/ivacaftor among cystic fibrosis lung transplant recipients. J Cyst Fibros 2022; 11: 56
    PubMedGoogle Scholar
  • 28 Saiman L. Improving outcomes of infections in cystic fibrosis in the era of CFTR modulator therapy. Pediatr Pulmonol 2019; 54 (Suppl. 03) S18-S26
    PubMedGoogle Scholar
  • 29 Hazlett HF, Hampton TH, Aridgides DS. et al. Altered iron metabolism in cystic fibrosis macrophages: the impact of CFTR modulators and implications for Pseudomonas aeruginosa (PA) survival. Sci Rep 2020; 10 (10935): 1-14
    CrossrefPubMedGoogle Scholar
  • 30 Shrestha CL, Zhang S, Wisniewski B. et al. (R)-Roscovitine and CFTR modulators enhance killing of multi-drug resistant Burkholderia cenocepacia by cystic fibrosis macrophages. Sci Rep 2020; 10 (01) 21700
    CrossrefPubMedGoogle Scholar
  • 31 Frost FJ, Nazareth DS, Charman SC, Winstanley C, Walshaw MJ. Ivacaftor is associated with reduced lung function infection by key cystic fibrosis pathogens: a cohort study using national registry data. Ann Am Thorac Soc 2019; 16 (11) 1375-1382
    CrossrefPubMedGoogle Scholar
  • 32 Heltshe SL, Mayer-Hamblett N, Burns JL. et al; GOAL (the G551D Observation-AL) Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor. Clin Infect Dis 2015; 60 (05) 703-712
    CrossrefPubMedGoogle Scholar
  • 33 McCullagh M, Wright L, Frost F. et al. Long term microbiological outcomes of ivacaftor use. A single-centre retrospective study. Pediatr Pulmonol 2017; 52: 346
    PubMedGoogle Scholar
  • 34 Gur M, Bar-Yoseph R, Toukan Y, Hanna M, Masarweh K, Bentur L. Twelve years of progressive Mycobacterium abscessus lung disease in CF-response to Trikafta. Pediatr Pulmonol 2021; 56 (12) 4048-4050
    CrossrefPubMedGoogle Scholar
  • 35 Lehr CJ, Pilewski JM. Cystic fibrosis: candidate selection and impact of the cystic fibrosis transmembrane conductance regulator therapy. Curr Opin Organ Transplant 2022; 27 (03) 198-203
    CrossrefPubMedGoogle Scholar
  • 36 Kutney KA, Sandouk Z, Desimone M, Moheet A. Obesity in cystic fibrosis. J Clin Transl Endocrinol 2021; 26: 100276
    PubMedGoogle Scholar
  • 37 Petersen MC, Begnel L, Wallendorf M, Litvin M. Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis. J Cyst Fibros 2022; 21 (02) 265-271
    CrossrefPubMedGoogle Scholar
  • 38 Hayes Jr. D, Darland LK, Hjelm MA, Mansour HM, Wikenheiser-Brokamp KA. To treat or not to treat: CFTR modulators after lung transplantation. Pediatr Transplant 2021; 25 (04) e14007
    CrossrefPubMedGoogle Scholar